David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ.
1] FAS Center for Systems Biology, Harvard University, Cambridge, Massachusetts 02138, USA [2] Society of Fellows, Harvard University, Cambridge, Massachusetts 02138, USA [3] Molecular Genetics & Microbiology and Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina 27708, USA. FAS Center for Systems Biology, Harvard University, Cambridge, Massachusetts 02138, USA. Division of Endocrinology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. Department of Bioengineering & Therapeutic Sciences and the California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, California 94158, USA.
Increased dietary exposure to choline, betaine, and trimethylamine-N-oxide (TMAO) predisposes cardiovascular disease patients to adverse cardiac events, such heart failure.
Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, Klein AL, Hazen SL.
Center for Cardiovascular Diagnostics and Prevention, Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, Ohio; Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: tangw@ccf.org. Center for Cardiovascular Diagnostics and Prevention, Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, Ohio. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Department of Mathematics, Cleveland State University, Cleveland, Ohio. Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand. Center for Cardiovascular Diagnostics and Prevention, Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland, Ohio; Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
This research was supported by National Institutes of Health grants P01HL076491, P01HL103453, P01HL098055, R01HL103866 (with Office of Dietary Supplements), R01HL103931, P20HL113452 and the Cleveland Clinic Clinical Research Unit of the Case Western Reserve University CTSA (UL1TR 000439). The main ADEPT study was supported in part by grant funding from American Society of Echocardiography, GlaxoSmithKline Pharmaceuticals, and Roche Diagnostics Inc. Mass spectrometry studies were performed within a Mass Spectrometry Core facility that is supported in part by a Center of Innovation Award by AB SCIEX.
Yes. Potential conflicts disclosure found
Drs. Hazen and Wang report being listed as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Dr. Hazen reports having been paid as a consultant or speaker for the following companies: Cleveland Heart Lab, Esperion, Lilly, Liposcience Inc., Merck & Co., Inc., Pfizer Inc., and Procter & Gamble. Dr. Hazen reports receiving research funds from Abbott, Cleveland Heart Lab, Liposcience Inc., Pfizer Inc., Procter & Gamble and Takeda Pharmaceuticals. Dr. Hazen reports having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from the companies shown below: Cleveland Heart Lab., Esperion, Frantz Biomarkers, LLC, Liposcience Inc., and Siemens. Dr. Hazen is also partially supported by a gift from the Leonard Krieger endowment and by the Foundaton LeDucq. All other authors have no disclosures to report.
Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL.
From the Department for Cellular and Molecular Medicine, Lerner Research Institute (W.H.W.T., Z.W., D.J.K., J.A.B., B.A.-B., X.S.L., B.S.L., S.L.H.); Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, OH (W.H.W.T., S.L.H.); and Department of Mathematics, Cleveland State University, OH (Y.W.). tangw@ccf.org hazens@ccf.org. From the Department for Cellular and Molecular Medicine, Lerner Research Institute (W.H.W.T., Z.W., D.J.K., J.A.B., B.A.-B., X.S.L., B.S.L., S.L.H.); Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, OH (W.H.W.T., S.L.H.); and Department of Mathematics, Cleveland State University, OH (Y.W.).
This research was supported by grants from the National Institutes of Health and the Office of Dietary Supplements (R01HL103866, P20HL113452). The GeneBank study has been supported by NIH grants P01HL076491, P01HL098055, R01HL103931, and the Cleveland Clinic Clinical Research Unit of the Case Western Reserve University CTSA (UL1TR 000439). Dr. Wang was partially supported by an American Heart Association Scientist Development Grant 12SDG12050473. Dr. Kennedy was partially supported by an American Heart Association Scientist Development Grant 14SDG18650010. Dr. Hazen is also partially supported by a gift from the Leonard Krieger endowment. Mass spectrometry studies were performed on instruments housed in a facility supported in part by a Center of Innovations Award by AB SCIEX.
Yes. Potential conflicts disclosure found
Drs.Wang, Levison and Hazen are named as co-inventor on pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and/or therapeutics. Dr. Hazen reports having been paid as a consultant for the following companies: Cleveland Heart Lab, Esperion, Liposcience Inc., and P&G. Dr. Hazen reports receiving research funds from Cleveland Heart Lab, Liposcience Inc., P&G and Takeda. Drs. Wang, Levison and Hazen report having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics and/or therapeutics from Cleveland Heart Lab, and Dr. Hazen also from the companies shown below: Siemens, Esperion, Frantz Biomarkers, LLC. All other authors have no relationships to disclose.
Djoussé L, Ellison RC, McLennan CE, Cupples LA, Lipinska I, Tofler GH, Gokce N, Vita JA.
Section of Preventive Medicine and Epidemiology, Evans Memorial Department of Medicine, Boston University School of Medicine, Massachusetts, USA. ldjousse@bu.edu
Maryse F. Bouchard, David C. Bellinger, Robert O. Wright, and Marc G. Weisskopf
Maryse F. Bouchard, Department of Environmental Health, Harvard School of Public Health, Boston, MA, US. Département de santé environnementale et au travail, Université de Montréal, Québec, Canada;
The anti-oxidant and anti-inflammation activities of the phytochemicals in whole grains may confer significant protection against the development and progression of type 2 diabetes.
To Promote and Encourage the Prevention and Reversal of Disease Through Personal Implementation of Practical Lifestyle Measures by Providing Starch-Smart® Health Education!
